BofA initiated coverage of Caris Life Sciences (CAI) with a Buy rating and $31 price target Caris is a molecular diagnostic company with a “differentiated, data-driven platform” for tissue-based tumor profiling, the analyst tells investors in a research note. The firm believes the company stands out due to its breadth of tests, artificial intelligence analysis, and high reimbursement rate. BofA believes Caris has a market leading financial profile and deserves a multiple above peers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences initiated with a Buy at Guggenheim
- Caris Life Sciences: Strong Market Position and Growth Potential Justify Buy Rating
- Caris Life Sciences publishes Assure liquid biopsy platform study
- Caris Life Sciences vice chairman Brille buys 30,000 common shares
- Opening Day: Caris jumps as investors buy into ‘AI TechBio company’